NASDAQ:CBUS - Nasdaq - US17166A1016 - Common Stock - Currency: USD
NASDAQ:CBUS (3/3/2025, 8:17:34 PM)
1.88
-0.17 (-8.29%)
The current stock price of CBUS is 1.88 USD. In the past month the price decreased by -24.5%. In the past year, price decreased by -90.48%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.9 | 373.71B | ||
AMGN | AMGEN INC | 15.68 | 166.89B | ||
GILD | GILEAD SCIENCES INC | 25.16 | 144.52B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1666.59 | 124.16B | ||
REGN | REGENERON PHARMACEUTICALS | 15.01 | 74.87B | ||
ARGX | ARGENX SE - ADR | 241.32 | 37.83B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.41B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.75B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.20B | ||
BIIB | BIOGEN INC | 8.6 | 20.65B | ||
NTRA | NATERA INC | N/A | 18.89B | ||
GMAB | GENMAB A/S -SP ADR | 24.69 | 14.59B |
Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. The company is headquartered in San Diego, California and currently employs 183 full-time employees. The company went IPO on 2017-07-20. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. The company is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). The company is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. The company has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
CIBUS INC
6455 Nancy Ridge Drive
San Diego CALIFORNIA US
Employees: 183
Company Website: https://www.cibus.com/
Investor Relations: https://ir.calyxt.com/
Phone: 18584500008
The current stock price of CBUS is 1.88 USD. The price decreased by -8.29% in the last trading session.
The exchange symbol of CIBUS INC is CBUS and it is listed on the Nasdaq exchange.
CBUS stock is listed on the Nasdaq exchange.
10 analysts have analysed CBUS and the average price target is 17.98 USD. This implies a price increase of 856.25% is expected in the next year compared to the current price of 1.88. Check the CIBUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CIBUS INC (CBUS) has a market capitalization of 63.69M USD. This makes CBUS a Micro Cap stock.
CIBUS INC (CBUS) currently has 183 employees.
CIBUS INC (CBUS) has a resistance level at 1.94. Check the full technical report for a detailed analysis of CBUS support and resistance levels.
The Revenue of CIBUS INC (CBUS) is expected to grow by 267.86% in the next year. Check the estimates tab for more information on the CBUS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CBUS does not pay a dividend.
CIBUS INC (CBUS) will report earnings on 2025-03-20, after the market close.
CIBUS INC (CBUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-14.79).
The outstanding short interest for CIBUS INC (CBUS) is 9.19% of its float. Check the ownership tab for more information on the CBUS short interest.
ChartMill assigns a fundamental rating of 2 / 10 to CBUS. Both the profitability and financial health of CBUS have multiple concerns.
Over the last trailing twelve months CBUS reported a non-GAAP Earnings per Share(EPS) of -14.79. The EPS decreased by -12.99% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -121.07% | ||
ROE | -411.87% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to CBUS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 60.45% and a revenue growth 267.86% for CBUS